Evidence map›Paper›PMID 29256110›Full record

ArticleClinical rheumatology2018

Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis.

Rosa Elda Barbosa-Cobos, Gustavo Lugo-Zamudio, Javier Flores-Estrada, Lizbeth Teresa Becerril-Mendoza, Pedro Rodríguez-Henríquez, Rubén Torres-González, Mario Adán Moreno-Eutimio, Julian Ramirez-Bello, José Moreno

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.International journal of molecular sciences · 2022
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rosa Elda Barbosa-CobosDepartment of Rheumatology, Hospital Juárez de México, Av. Instituto Politécnico Nacional 5160, Delegación: Magdalena de las Salinas, 17760, Mexico City, Mexico. rebcob@yahoo.com.
Gustavo Lugo-ZamudioDepartment of Rheumatology, Hospital Juárez de México, Av. Instituto Politécnico Nacional 5160, Delegación: Magdalena de las Salinas, 17760, Mexico City, Mexico.
Javier Flores-EstradaResearch Unit, Hospital Juárez de México, Mexico City, Mexico.
Lizbeth Teresa Becerril-MendozaDepartment of Rheumatology, Hospital Juárez de México, Av. Instituto Politécnico Nacional 5160, Delegación: Magdalena de las Salinas, 17760, Mexico City, Mexico.
Pedro Rodríguez-HenríquezDepartment of Rheumatology, Hospital Manuel Gea González, Mexico City, Mexico.
Rubén Torres-GonzálezHospital de Traumatología y Ortopedia, UMAE 'Magdalena de las Salinas' IMSS, Mexico City, Mexico.
Mario Adán Moreno-EutimioResearch Unit, Hospital Juárez de México, Mexico City, Mexico.
Julian Ramirez-BelloResearch Unit, Hospital Juárez de México, Mexico City, Mexico.
José MorenoResearch Unit, Hospital Juárez de México, Mexico City, Mexico.
Hospital Juárez de México · MXInstituto Politécnico Nacional · MXHospital General Dr. Manuel Gea Gonzalez · MX

Funding

Hospital Juárez de México HJM2280/13-A
6 · The paper itself

Abstract

The aim of the is study is to examine the role of serum substance P (SP) levels as a simple biomarker for rheumatoid arthritis (RA) disease activity, its correlation with other markers of disease activity, and with selected clinical parameters. The study comprised 90 RA patients and 24 healthy controls. RA activity was assessed by means of the disease activity 28-C-reactive protein (DAS28-CRP) index and ultrasound power Doppler (USPD) by the German ultrasound score based on seven joints. SP serum values were obtained by means of an ELISA commercial kit. Statistics were achieved by the Student's t test and Spearman correlation analysis with Bonferroni correction. As a group, RA patients had significantly increased levels of SP compared with healthy controls (p < 0.0001). SP levels correlated with DAS28-CRP (r = 0.5050, p < 0.0001), number of tender joints (NTJ, r = 0.4668, p < 0.0001), number of swollen joints (NSJ, r = 0.4439, p < 0.0001), visual analogue scale (VAS, r = 0.5131, p < 0.0001). However, SP did not correlate with CRP levels (r = 0.0468, p = 0.6613), nor with the USPD (r = 0.1740, p = 0.1009). Elevated serum SP is a common feature of RA patients, which also appears to correlate with clinical measurements of disease activity and with subjective clinical data (NTJ and VAS). Thus, although SP is higher in RA patients with high disease activity, it also detects subtle RA disease activity even in patients in apparent remission, which suggests its usefulness for therapeutic decisions.

Indexed as

AdultArthritis, RheumatoidBiomarkersC-Reactive ProteinFemaleHumansInflammationMaleMiddle AgedSeverity of Illness IndexSubstance PUltrasonographyYoung AdultBiomarkersC-Reactive ProteinSubstance PBiomarker and C-reactive proteinDisease activityRheumatoid arthritisSubstance P

Identifiers

PMID29256110
OpenAlexW2771897522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.